Document:

Addendum No. 1 to Collaboration and License Agreement

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  
 EXHIBIT 10.9 

ADDENDUM NO. 1 
 TO
COLLABORATION AND LICENSE AGREEMENT 
 THIS ADDENDUM NO. 1 TO
COLLABORATION AND LICENSE AGREEMENT (the “Addendum”) is made and entered into effective as of January 21, 2011 (the “Addendum Effective Date”) by
and among ALDERBIO HOLDINGS LLC (“AlderHoldings”), a Nevada limited liability company having its principal place of business at 101 Convention Center Drive, Suite 850, Las Vegas,
Nevada 89109, ALDER BIOPHARMACEUTICALS INC., a Delaware corporation having its principal place of business at 11804 North Creek Parkway South, Bothell, Washington 98011
(“AlderBio”) and BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation having offices at 345 Park Avenue, New
York, New York 10154 (“BMS”). Alder Holdings and AlderBio are collectively referred to herein as “Alder”. 
 The Parties
entered into that certain Collaboration and License Agreement dated as of November 6, 2009 (the “Agreement”). 
 The purpose of this
Addendum is to confirm that Alder and BMS have agreed to undertake, pursuant to the Agreement, certain activities and to specify the terms and conditions agreed upon by Alder and BMS with respect to such activities. 

All capitalized terms that are used in this Addendum but are not defined herein shall have the meanings given to them in the Agreement. 

As contemplated by Section 6.3(b)(ii) of the Agreement, BMS has notified Alder that it desires to receive and use (solely as permitted by the last
sentence of Section 6.3(b)(ii) of the Agreement) the Alder Future Process Know-How for the Future Process developed by [***] pursuant to [***] (such Future Process, the “B2 Process”). Pursuant to Section 6.3(b)(ii) of the
Agreement, BMS is obligated to reimburse Alder for fifty percent (50%) of all past and future documented out-of-pocket costs and expenses incurred by Alder in connection with the development or optimization of the B2 Process by [***]. Such
reimbursement obligation is subject to the $[***] reimbursement cap specified in Section 6.4(a)(ii) of the Agreement. Since Alder has already incurred more than $[***] in out-of-pocket costs and expenses in connection with the development or
optimization of the B2 Process by [***], BMS is obligated to reimburse Alder for $[***] of such costs and expenses. Notwithstanding the procedures and time periods specified in the fifth
(5th) and seventh (7th) sentences of Section 6.3(b)(ii) of the Agreement for BMS’ reimbursement of such costs and expenses,
Alder shall provide BMS with an invoice for $[***] on or promptly after the Addendum Effective Date (as defined above) and another invoice for $[***] on the earlier of (a) the Completion Date (as defined below) or (b) June 30, 2011.
BMS shall pay to Alder each invoiced amount within [***] after the receipt of the applicable invoice.  
 Alder and BMS desire to avoid potential
future insufficiency of ALD518 supply and have agreed to undertake certain work directed to optimizing the production strain for ALD518 and to improving the process for manufacturing ALD518. The goal of such work is an improved manufacturing process
that, when implemented with the optimized production strain, produces 

  

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 
[***] of purified ALD518 [***] (the “Goal”). The Parties wish to implement such improved manufacturing process prior to initiating manufacture of ALD518 for use in Phase 3
Clinical Trials. The scope, activities and timelines for such work and the Parties’ rights and obligations with respect thereto are as follows: 
  

	 	1.	The work to be conducted is described in Exhibit A (the “Work Plan”). Since the Work Plan includes making changes to the production strain for ALD518 (which is defined in the Agreement as Production
Strain Work), the Work Plan is deemed to be a Production Strain Work Plan as contemplated by Section 6.8 of the Agreement and the Parties’ performance of the Work Plan will be overseen by the JMC or a subcommittee thereof as contemplated
by Section 6.8 of the Agreement. 

  

	 	2.	Alder shall be responsible for conducting the strain development activities specified in the Work Plan. Alder and BMS shall be jointly responsible for conducting the process improvement activities specified in the Work
Plan and will use the current optimized ALD518 manufacturing process developed pursuant to [***] (the “B2 Process”) as the starting point for such activities. 

 

	 	3.	Each Party shall use commercially reasonable efforts to conduct and complete the Work Plan activities allocated to it within the timeframe specified in the Work Plan; provided, however, that neither Party shall have any
obligation to continue performance of the Work Plan after the earlier of: (i) the date of achievement of the Goal (such date, the “Completion Date”); or (ii) [***]. It is expected that the work as set forth in the Work
Plan will be completed on or before [***]. 

  

	 	4.	As specified in Section 6.8 of the Agreement, BMS is to reimburse Alder for out-of-pocket costs and FTE costs (at the FTE Rate) with respect to performing Production Strain Work. Accordingly, BMS shall reimburse
Alder for documented out-of-pocket costs and FTE costs (at the FTE Rate) incurred by Alder in the performance of the strain development work specified in the Work Plan in accordance with this Addendum, provided that (i) Alder’s
out-of-pocket costs and the level of FTE effort shall be consistent with the applicable provisions of Exhibit A (or an amendment thereto or as otherwise approved in writing by both Parties in advance of being incurred) and (ii) Alder’s
total out-of-pocket costs and FTE costs (at the FTE Rate) with respect to such strain development work shall not exceed $[***] without approval in writing by both Parties. Alder has already incurred [***] in the course of performing strain
development activities specified in the Work Plan prior to October 1, 2010. On or promptly after the Addendum Effective Date, Alder shall send an invoice to BMS for such amount and BMS shall pay such invoiced amount to Alder within [***] after
the receipt of such invoice. Within [***] after each calendar quarter between the Addendum Effective Date and [***], Alder shall provide BMS with an invoice setting forth the out-of-pocket costs and FTE costs (at the FTE Rate) incurred during such
calendar quarter (and for the first such invoice, during the period between October 1, 2010 and the Addendum Effective Date) in the course of performing the strain development work specified in the Work Plan in accordance with this Addendum and
shall include with such invoice reasonable documentation for such costs. BMS shall pay Alder the amount correctly invoiced within [***] after BMS’ receipt of the invoice. 

  
 -2- 

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

	 	5.	Each Party shall bear all costs it incurs in the course of performing process improvement activities specified in the Work Plan. 

  

	 	6.	Alder and BMS shall share equally all documented out-of-pocket costs and FTE costs (at the FTE Rate) incurred by either Party in the course of performing analytical characterization work specified in the Work Plan in
accordance with this Addendum, provided that (i) such out-of-pocket costs and the level of FTE effort shall be consistent with the applicable provisions of Exhibit A (or an amendment thereto or as otherwise approved in writing by both Parties
in advance of being incurred) and (ii) each Party’s total out-of-pocket costs and FTE costs (at the FTE Rate) for such analytical characterization work shall not exceed $[***] without approval in writing by both Parties. Within [***] after
each calendar quarter between the Addendum Effective Date and [***], [***] shall provide [***] with an invoice setting forth fifty percent (50%) of the out-of-pocket costs and FTE costs (at the FTE Rate) incurred by such Party during such
calendar quarter in the course of performing the analytical characterization work specified in the Work Plan in accordance with this Addendum and shall include with such invoice reasonable documentation for such costs. The other Party shall pay such
Party the amount correctly invoiced within [***] after the receipt of the invoice. 

  

	 	7.	Alder and BMS hereby agree that the FTE Rate with respect to the Parties’ performance of the Work Plan in accordance with this Addendum shall be [***] per FTE per year. 

 

	 	8.	If the Parties’ performance of the Work Plan in accordance with this Addendum results in achievement of the Goal, then the ALD518 manufacturing process created thereby shall be deemed the “B3
Process”. The technical transfer and implementation of the B3 Process to a Third Party manufacturer is outside the scope of this Addendum and will be subject to a separate agreement between the Parties. 

 

	 	9.	On or about [***], Alder and BMS shall assess the progress and accomplishments of the Parties’ performance of the Work Plan and will discuss what, if any, additional work would need to be performed after [***] to
further the B3 Process or to achieve the Goal. Any additional work would be performed pursuant to a separate written agreement between the Parties or an addendum to this Addendum. 

 

	 	10.	The Parties acknowledge that, in accordance with Section 6.8 of the Agreement, any production strain generated pursuant to Parties’ performance of the Work Plan in accordance with this Addendum shall be deemed
Alder Material for all purposes of the Agreement, and BMS shall use such production strain solely in accordance with, and subject to the terms and conditions of, the Agreement. 

 

	 	11.	 The Parties acknowledge and agree that any and all inventions and Information conceived, discovered, developed or otherwise made by or on behalf of
either Party in the course of conducting the Work Plan shall be Sole Inventions and Joint Inventions, as the case may be, subject to Sections 7.1 and 9.2 of the Agreement. The Parties acknowledge and agree that any such Sole Inventions of BMS shall
be deemed to be BMS Improvements, subject to the license to Alder under Section 7.8 of the Agreement and the restrictions set forth in Section 7.14. BMS’ rights and licenses with respect to the use and practice of the Alder Mab Xpress
Technology are limited to those rights and licenses set 

  
 -3- 

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

	 	
forth in Sections 7.4(iii) and 7.9(d) of the Agreement. Accordingly, BMS may be required to obtain additional license(s) to the Alder Mab Xpress Technology in order to use and practice such Sole
Inventions of BMS and such Joint Inventions for other purposes. For the purposes of Article 12 of the Agreement, (i) Information generated by Alder in the performance of the Work Plan shall be deemed to be Confidential Information of Alder
(notwithstanding the penultimate sentence of Section 12.1) and (ii) Information generated by BMS in the performance of the Work Plan shall be deemed to be Confidential Information of both Parties. Notwithstanding the last sentence of
Section 12.1, BMS agrees that Alder may use Information generated by BMS in the performance of the Work Plan for any purpose that does not violate Article 11 or Applicable Law, subject to the [***] licenses granted by Alder to BMS under Article
7 and, with respect to Publication, subject to Section 12.4. BMS confirms that its use of any Alder Material (and any derivatives, parts or progeny thereof) shall be subject to the restrictions set forth in the Agreement, including without
limitation those set forth in Section 7.13. 

  

	 	12.	The Parties acknowledge that the Work Plan is being conducted under the Agreement and all terms and conditions of the Agreement, except as expressly set forth in this Addendum, apply to the Parties’ performance of
the Work Plan. 

 This Addendum will become effective as of the Addendum Effective Date and shall continue in effect, except to the extent it
is amended or terminated in accordance with Section 17.1 of the Agreement, throughout the remainder of the Term. 
 This Addendum is hereby
incorporated into and made part of the Agreement. All the terms and conditions of the Agreement remain in full force and effect, except as expressly indicated otherwise in this Addendum. 

IN WITNESS WHEREOF, the Parties have caused this Addendum to be executed by their duly
authorized representatives effective as of the Addendum Effective Date. 
  

									
	ALDER BIOPHARMACEUTICALS INC.	 		 	ALDERBIO HOLDINGS LLC
					
	By: 	 	/s/ Randall C. Schatzman	 		 	By: 	 	/s/ Randall C. Schatzman
		 	 Randall C. Schatzman, Ph.D
 President and Chief
Executive Officer
	 		 		 	 Randall C. Schatzman, Ph.D

Manager

  

			
	BRISTOL-MYERS SQUIBB COMPANY
		
	By:	 	/s/ John Tabor
	 Name:
 Title:
	 	 John Tabor
 VP, BTPM

  
 -4- 

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 Exhibit A 

to Addendum No.1 
 1. Summary of
Strain and Process Improvement Activities 
 1.1. Statement of Goals for the Strain and Process Improvement 

The goal of the strain and process improvement activities are to generate an improved Pichia pastoris strain and/or manufacturing process with
an overall target productivity of [***] purified protein [***] of fermentation volume while maintaining or improving current product quality. The approach is that a combination of [***] will yield that target. 

1.2. Strain Development Activities (to be carried out by Alder) 
  

	 	•	 	[***] in Pichia pastoris 

  

	 	•	 	Test promising leads in optimized process to evaluate specific potential (specific productivity, whole-broth titer, genetic stability) 

 

	 	•	 	[***] suitable for commercial production of ALD 518. 

  

	 	•	 	Strain-specific optimization of lead production strains 

  

	 	•	 	Provide lead production strains to BMS for further evaluation. 

 1.3. Process Improvement Activities of B2
Process (to be carried out by Alder and BMS) 
  

	 	•	 	Technical transfer of the B2 Process to BMS at the [***]. 

  

	 	•	 	Continued work on the fermentation process potentially with the new lead strains to maximize titer while maintaining product quality (build on work already performed for B2 Process) 

 

	 	•	 	Optimize operating parameters ([***]) 

  

	 	•	 	[***] 

 1.4. Analytical characterization of product quality (work to be done at BMS or outsourced) 

2. Details of the Improvement Activities 
 2.1
Strain Development Activities 
 2.1.1. [***] 

Targeting of [***] will be tested to: 
  

	 	(a)	[***] 

  

	 	(b)	[***] 

  
 -5- 

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

	 	(c)	[***] 

  

	 	(d)	lead candidate strains will be transferred to BMS for process improvement studies. 

 2.1.2. [***] Development

  

	 	(a)	Current [***] products have been established to be generated via targeting [***] ALD518 

  

	 	(b)	Assessment of the genome will be conducted to identify additional members of [***] 

  

	 	(c)	A strategy[***] will be developed and implemented to assess product quality as well as strain productivity and stability 

  

	 	(d)	If necessary, [***] will be prepared and characterized as above 

 2.1.3. On-going technology development 

A number of additional enhancements of the production platform will be under investigation as Mab Xpress undergoes its next level of
enhancement. It is anticipated that some of these advancements may be applicable to the commercial process for producing ALD518. Outcomes of this work fall outside the scope of this Addendum. 

2.1.4. Estimated Cost Projections for Strain Development Activities 

Total Project Cost of Strain Development Activities at Alder: ~$[***] 

 

	 	(a)	Alder Yeast Expression Work prior to Nov. 2010: ~[***] FTE [***]; ~$[***] 

  

	 	(b)	~[***] man months at Alder ([***]): ~$[***] 

 2.2. Process Improvement Activities 

Outside of these activities is the ongoing [***] support by Alder for the B2 Process (costs are included in the costs and BMS reimbursement payment for the B2
Process as set forth in the Addendum) 
 2.2.1. Tech Transfer to establish B2 Process at BMS 

 

	 	•	 	Gary Lesnicki to Syracuse mid December, completed 

  

	 	•	 	Z. Li to visit Alder, pending 

  

	 	•	 	Goal: comparable data using same protocol 

 2.2.2. Assay Transfer to BMS if applicable 

 

	 	•	 	Titer—[***] standardization between Alder and BMS 

  

	 	•	 	Purity—[***] method standardization between Alder and BMS 

 2.2.3. Screening of new strains at Alder at
the [***] fermentation scale 
  

	 	•	 	This activity will start at Alder in [***]. 

  

	 	•	 	Each run set contains [***] parallel fermentations 

  

	 	•	 	Total successful run sets: [***] 

  

	 	•	 	FTE requirements: [***] 

  
 -6- 

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 2.2.4. Purification at Alder of lead strain candidates ([***]) 

To assess behavior of molecule during purification and for product quality assessment 

 

	 	•	 	Assumption: [***] 

  

	 	•	 	[***] purifications x [***] x [***] FTEs equals [***] 

 2.2.5. Fermentation process improvement at BMS at the
[***] fermentation scale 
 Requires successful process transfer to BMS (see 2.2.1.). 

The goal is to optimize the fermentation conditions for yield and scalability. 

 

	 	•	 	This activity will start at BMS in [***]. 

  

	 	•	 	Each run set contains [***] parallel fermentations 

  

	 	•	 	Total successful run sets: [***] 

  

	 	•	 	FTE requirements: [***] x [***] x [***] FTEs equals [***] 

 2.2.6. Estimated Cost Projections for Process
Development Activities 
 Approximately [***]: ~$[***] 

2.3. Analytical Characterization 
 Work will be required
for analytical characterization of the lead candidates. This will include [***] and [***]. Depending on resource availability this work could be done by BMS in-house or outsourced. Total cost not to exceed $[***] per Party as set forth in
paragraph 6 of the Addendum. 
 3. Summary of Estimated Costs 
  

							
	 Activity
	  	 Total Cost
	  	 Cost incurred by Alder
	  	 Cost incurred by BMS

				
	Strain Development1	  	[***]	  	[***]	  	[***]
				
	Process Development2	  	[***]	  	[***]	  	[***]
				
	Analytical Characterization3	  	[***]	  	[***]	  	[***]

  

	1 	[***]. 

	2 	[***]. 

	3 	[***]. 

 Page 8 to follow. 

  
 -7- 

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 Timeline—[***] 

[***]Master Services Agreement

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
 EXHIBIT 10.10 

MASTER SERVICES AGREEMENT 
 THIS
MASTER SERVICES AGREEMENT (this “Agreement”) is effective as of October 14, 2013 (the “Effective Date”) and is entered into among Alder Biopharmaceuticals Inc., a Delaware corporation (“Alder”)
having its principal place of business at 11804 North Creek Parkway South, Bothell, WA 98011, USA, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., a Delaware corporation (“FDBU”), formerly known as Diosynth RTP Inc., having its
principal place of business at 101 J. Morris Commons Lane, Morrisville, NC 27560 USA, and FUJIFILM Diosynth Biotechnologies UK Limited (“FDBK”), having its principal place of business at Belasis Avenue, Billingham, TS23 1LH, United
Kingdom (each a “Party”, and, two or all of them, collectively, the “Parties”). In this Agreement, the term “Fujifilm” means, individually and collectively, as the context requires, FDBU and/or
FDBK. 
 The Parties intend that, under this Agreement, from time to time, Alder may desire FDBU and/or FDBK to carry out Programs in relation to the
production of Products, and FDBU and FDBK may agree to carry out Programs in relation to the production of Products, under the terms of this Agreement and the applicable Statements of Work (all as defined below). 

Now, therefore, for good and valuable consideration, the sufficiency and receipt of which are hereby acknowledged, the Parties agree as follows: 

Definitions: 
 “Affiliate” shall mean in
relation to any Party, any corporation, association or other business entity which directly or indirectly controls, is controlled by or is under common control with such Party, and “control” shall mean the legal power to direct or cause
the direction of the general management and policies of such entity whether through the ownership of at least 50% of voting securities or capital stock of such business entity or any other comparable equity or ownership interest with respect to a
business entity other than a corporation. 
 “Agreement” shall mean this Agreement (as defined in the preamble), and, as the context
requires, this Agreement together with the Quality Agreement, the applicable Statements of Work, and any other documents or agreements incorporated by reference into this Agreement from time to time. 

“Alder” shall mean Alder Biopharmaceuticals, Inc. 

“Alder’s Confidential Information” shall have the meaning set forth in Section 7(a). 

“Alder Process Invention” shall have the meaning set forth in Section 9(a). 

“Alder Technology” shall mean all materials, reagents and processes (together with associated data and information) owned or possessed by
Alder and their progeny and derivatives, associated with [***], transferred to Fujifilm for use during a Program or transferred to Fujifilm for use under the Prior Agreement. The foregoing includes, without limitation, [***]. Alder Technology shall
be included within Alder Confidential Information. 
 “Assumptions” shall have the meaning set forth in Section 6(a). 

“Batch” shall mean the quantity of Product derived from a single run of the Process under this Agreement. 

  
 1. 

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 “Batch Cancellation Fee” shall mean the applicable sum, if any, detailed in the applicable
Statement of Work payable by Alder as a result of its cancellation of a GMP Batch or GMP Batches. A Batch Cancellation Fee is a type of “Cancellation Fee”. 

“Campaign Cancellation fee” shall mean the applicable sum, if any, detailed in the applicable Statement of Work payable by Alder as a result
of its cancellation of an entire GMP Campaign or termination of a GMP Program. A Campaign Cancellation Fee is a type of “Cancellation Fee”. 

“cGMP” shall mean the regulatory requirements for Current Good Manufacturing Practices which are applicable to the circumstances in which the
term is being used, as each may be amended from time to time, including without limitation the U.S. Federal Food, Drug, and Cosmetic Act, as amended, and its implementing regulations, and Directive 91/356/EEC, as amended by 2003/94/EC, and the Guide
to Good Manufacturing Practice (Volume 4 of “The rules governing medicinal products in the European Union”), including the Rules and Guidance for Pharmaceutical Manufacturers and Distributors 2007 part II: Basic Requirements for Active
Substances used as Starting Materials, and ICHQ7 — as incorporated in the EU in Annex 18 to the GMP Guide, and in the USA in the Federal Register volume 86 No 186 (ICHQ7). 

“Claim” shall have the meaning set forth in Section 15(a). 

“Confidential Information” shall mean Alder’s Confidential Information and/or Fujifilm’s Confidential Information, as the context
requires. 
 Conforming GMP Batch and Conforming GNP Product: A GMP Batch (or, as the context requires, GMP Product) that meets all of the following
requirements: 
  

	 	(i)	has been manufactured in compliance with all cGMP requirements; 

  

	 	(ii)	conforms to the Product Specification; and 

  

	 	(iii)	conforms to all of the additional requirements, if any, set forth in the applicable Statement of Work. 

“Disposition” shall mean the stage during a Program or the process by which all data, records and documentation (including executed batch
manufacturing records) related to cGMP manufacture of each GMP Batch is reviewed. 
 “Disposition Package” shall mean the compilation of
data, records and documentation for a GMP Batch, including but not limited to, executed batch manufacturing records, genealogy, certificate of analysis (“COA”) and associated Quality Control data, and any other data, records or
documentation required under the Quality Agreement. 
 “Drug Product” shall mean the final dosage form of the Product which [***] and which
contains Product in association with other active or inactive ingredients. 
 “Facility” shall mean, with respect to FDBU, its
manufacturing facility at [***], and, with respect to FDBK, its development and manufacturing facility at [***], or such other facility or facilities identified in the applicable Statement of Work, as the context requires. 

“Fujifilm’s Confidential Information” shall have the meaning set forth in Section 7(b). 

“Fujifilm Factor” shall mean any of the following factors: (a) [***], (b) the [***], (c) the [***]; (d) the [***], or
(e) the [***]. For the avoidance of doubt, [***]. 

  
 2 

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 “Fujifilm Process Invention” shall have the meaning set forth in Section 9(a). 

“GMP Batch” shall mean a Batch which is identified in a Statement of Work as a GMP Batch and which is or is intended to be manufactured
during a GMP Stage and subject to Disposition, all in accordance with cGMP, and “GMP Product” shall mean the Product from or in the GMP Batch. 

“GMP Stages” shall mean the Stages of a Program identified in the applicable Statement of Work during which activity associated with cGMP
manufacture of Product is or is intended to take place, including cGMP preparation, engineering runs, cGMP manufacturing (including production and pre- and post-manufacturing cleaning, as well as any cleaning required between Batches), Disposition
and reporting. 
 “Impasse Notice” shall have the meaning set forth in Section 6(b). 

“Issued Batch Record” shall mean the batch record Instruction issued from the Master Batch Record for completion in production. 

“Legal Requirements” shall mean all laws, rules, regulations, ordinances, guidance, guidelines, and standards of any governmental or
regulatory authority which are applicable to the circumstances in which the term “Legal Requirements” is used, including without limitation (a) cGMP, (b) the regulations and regulatory guidance promulgated by the FDA, the MHRA or
the EMA (and, subject to express prior written agreement of the Parties, other applicable Regulatory Authorities), and (c) all laws and regulations requiring permits, licenses, filings or certifications with respect to Alder, Fujifilm, a
Facility, or the manufacture of Product or performance of other obligations under this Agreement. 
 “manufacture” or
“produce” shall mean all steps and activities performed or to be performed by Fujifilm to produce Product, as set forth in the applicable Statement of Work, including, as applicable, the manufacturing, formulation, filling,
finishing, packaging, inspection, labeling, testing, quality control, disposition, release, shipping and storage of Product. 
 “Master Batch
Record” shall mean the document which sets out in detail the master production instructions for production of Product, as defined in sections 6.4 and 6.5 of the Rules and Guidance for Pharmaceutical Manufacturers and Distributors Part II:
Basic Requirements for Active Substances Used as Starting Materials. The Master Batch Record, and any changes thereto, must be reviewed and approved by both Parties. 

“Modification” shall have the meaning set forth in Section 6(a). 

“Non-Conforming GMP Batch” and “Non-Conforming GMP Product” shall mean any GMP Batch or any Product from a GMP Batch which
fails to meet any of the following requirements: (i) has been manufactured in compliance with all cGMP requirements; and (ii) conforms to the Product Specification; and (iii) conforms to all of the additional requirements, if any, set
forth in the applicable Statement of Work. 
 “Non-GMP Stages” shall mean the Stages of a Program other than GMP Stages. 

  
 3 

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 “Party” or “Parties” shall have the meaning set forth in the preamble. As
the context requires, the phrase “either Party” or “the Parties” refers to Alder, on the one hand, and FDBU and/or FDBK, on the other hand. 

“Prior Agreement” shall mean the bioprocessing services agreement between Alder and FDBU dated [***] (as may have been amended in writing by
the Parties from time to time, the “Prior BSA”) under which Fujifilm provided bulk drug manufacturing services and/or the quality agreement between Alder and FDBU that is related to the Prior BSA (the “Prior
QA”). 
 “Process” shall mean the process for manufacture of a Product. 

“Process Consumable” or “Consumable” shall mean a consumable item used or intended for use in a Program including, without
limitation, reagents, raw materials, packaging components, chromatography resins, filters, filtration membranes, media, buffer bags, refold bags, tubing, hoses, disposable analytical test kits, in-process measurement probes, analytical columns and
disposable containers. 
 “Process Specification” shall mean the document which defines all steps in the Process, including any
critical processing parameters and in-process specifications. 
 “Product” shall mean the proprietary product of Alder which is the
subject of a Program as identified in the applicable SoW. When the context requires, the term “Product” also means the tangible forms of Product which are or are to be manufactured by Fujifilm under this Agreement. 

“Product Invention” shall have the meaning set forth in Section 9(a). 

“Product Specification” shall mean the qualitative, quantitative, functional and analytical specifications that describe testing methods and
acceptance criteria for Product, as set out in the quality documents, as agreed and as amended from time to time by the Parties. 

“Program” shall mean the services to be performed under this Agreement and the applicable Statement of Work, as set out in the applicable
Statement of Work. 
 “Program Amendment Order” or “PAO” shall mean a document detailing changes to the Agreement
and/or a Program, in each case as agreed and signed by the applicable Parties. 
 “Program Price and Payment Schedule” shall mean
the program price and payment schedule attached to or contained in the applicable SoW. 
 “Quality Agreement” shall mean the quality
agreement dated as of the Effective Date entered into by the Parties. 
 “SoW” or “Statement of Work” shall mean
the scope of work or statement of work agreed and signed by the applicable Parties setting out in detail the work to be undertaken during a Program. As the context requires, references to a “Scope” shall be deemed references to the
applicable Statement of Work, with the appropriate changes having been made, mutatis mutandis. 
 “Work Output” shall have the
meaning set forth in Section 8(a). 
 References in this Agreement to “Schedules” refer to the Schedules incorporated into this Agreement.
References to Sections and Clauses are references to sections and clauses in this Agreement unless specified otherwise. References to the singular include the plural and vice versa, and “include” and “including”, etc., means
including without limitation. 

  
 4 

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 Section 1. 

SoWs /Performance of Programs 
  

	 	a)	From time to time, at Alder’s request, the Parties will agree on Programs to be undertaken. It is intended and the Parties agree that each Program will be subject to a separate, numbered, Statement of Work (being
“Statement of Work #1”, “Statement of Work #2”, etc.). It is intended and the Parties agree that each Statement of Work shall be signed by Alder and FDBU and/or FDBK, depending on which of them shall be the primary party to
perform the work defined under such Statement of Work, and, once its terms are agreed and, on signature, the Statement of Work shall be subject to the terms of and incorporated into this Agreement by this reference. 

 

	 	b)	Fujifilm shall perform its obligations in accordance with and as set forth in this Agreement, the Statements of Work and the Quality Agreement. Without limitation, Fujifilm will timely and diligently perform each
Program for Alder in accordance with the terms and conditions of this Agreement, the applicable SoW and the Quality Agreement through the devotion of a sufficient number of persons of requisite skill and training. Subject to and in each case as
limited by Section 1(g) and Section 1(h), Alder may require that any deficient or defective Program services be reperformed or corrected, at Fujifilm’s expense. 

 

	 	c)	Terms defined in the main body of this Agreement shall have same meaning when used in the Sow or Quality Agreement, unless a different meaning is given therein. in the event of any conflict between or among the
component parts of this Agreement, then, unless the Parties expressly agree that a particular clause will control over all other component parts, the following order of precedence shall apply: 

 

	 	1.	the provisions in the main body of this Agreement; 

  

	 	2.	the provisions in the Quality Agreement and 

  

	 	3.	the provisions in the SoW. 

  

	 	d)	Alder shall perform its obligations in accordance with and as set forth in this Agreement, the applicable SoW and the Quality Agreement, shall support and cooperate with the execution of each Program and shall not
knowingly engage in any act or omission, which may reasonably be expected to prevent or delay the successful execution of a Program. The foregoing shall not be construed in derogation of Alder’s rights to terminate this Agreement pursuant and
subject to the terms of this Agreement. 

  

	 	e)	Fujifilm warrants (as of the time of delivery) and covenants, as applicable, that all Product is and will be [***]. Fujifilm warrants (as of the time of delivery) and covenants, as applicable, that, with respect to each
non-GMP Batch that is a development batch, Fujifilm has [***] to ensure that the [***] (including [***]) set forth in the applicable documents. Fujifilm warrants (as of the time of delivery), and covenants, as applicable, that each GMP Batch and all
GMP Product: [***]. 

  

	 	f)	 Fujifilm shall provide Alder’s quality assurance department with a Disposition Package within [***] of completion of Disposition of each GMP
Batch by Fujifilm and (if appropriate) a recommendation for such batch to be released and, if requested samples of such Batch. Within [***] after Alder’s receipt of the Disposition Package together with any requested samples, Alder shall review
the Disposition Package in order to determine, to the extent reasonably ascertainable therefrom and subject to Alder’s rights below, whether it agrees with Fujifilm’s findings in the Disposition Package, and, in particular, with
Fujifilm’s determination of conformity or non-conformity. Any complaints of non-conformity by Alder in relation 

  
 5 

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

	 	
to the Disposition Package shall be delivered to Fujifilm in writing within [***] after receipt by Alder of the Disposition Package together with any requested samples (or, in the case of a
latent non-conformity that was not readily ascertainable therefrom, within [***] after discovery of such latent non-conformity and in any case within [***] following delivery of the Disposition Package), accompanied by supporting data.

 If the Parties do not agree on Fujifilm’s findings in the Disposition Package, and, in particular, with Fujifilm’s
determination of conformity or non-conformity, or [***], the matter shall be [***]. 
  

	 	g)	The following provisions shall apply if Fujifilm determines or the Parties agree [***] that there is Non-Conforming GMP Product: 

  

	 	(i)	The Non-Conforming GMP Product shall not be delivered to Alder, unless Alder requests it. If Alder requests delivery of the Non-Conforming Product, Fujifilm shall deliver such Non-Conforming Product. If Alder requests
delivery of the Non-Conforming GMP Product, and the parties agree on an equitable price for the Non-Conforming GMP Product (which shall be negotiated in good faith by the parties), then, unless prohibited by applicable Legal Requirements, Fujifilm
shall deliver such Non-Conforming GMP Product in accordance with Section 12(a) and Alder shall pay to Fujifilm the agreed price. 

  

	 	(ii)	[Reserved] 

  

	 	(iii)	The following provisions shall apply if the non-conformity was not caused by any Fujifilm Factor: 

  

	 	(1)	Alder shall be obliged to make payment for the manufacture of such Non-Conforming Batch as set out in the applicable Program Price and Payment Schedule. 

 

	 	(2)	if Alder wishes Fujifilm to carry out additional work under a Program, such additional work, including the rework or reprocessing of the Non-Conforming GMP Product or the manufacture of a new GMP Batch, shall be carried
out at a time to be agreed and subject to agreement of the price payable in respect of such rework, reprocessing or further manufacture, such agreement to be recorded in a PAO. 

 

	 	(iv)	The following provisions shall apply if the non-conformity was caused by any Fujifilm Factor(s): Fujifilm shall, at Alder’s option: 

 

	 	(1)	Subject to Section 1(g)(iv)(2) below, replace the Non-Conforming GMP Product with Conforming GMP Product, at no additional cost to Alder, either through rework or reprocessing of the Non-Conforming GMP Batch (if
Alder consents to such rework or reprocessing), or additional manufacture of Conforming GMP Product, all of which shall be undertaken at Fujifilm’s cost and expense (including with respect to Consumables), as soon as reasonably practicable. For
clarity, under this option, the payment due at or following completion of the manufacture of the GMP Batch shall not be due until the date on which the replacement Product is Dispositioned and agreed to be Conforming GMP Product by both parties
[***] 

  
 6 

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 [***]. Subject to availability of Consumables, Fujifilm shall use commercially reasonable
efforts to initiate such replacement within [***] of the date on which Fujifilm determines or the Parties agree (or, in the absence of agreement, [***]) that there is Non-Conforming GMP Product. 

 

	 	(2)	If (A) Fujifilm is unable to or if Fujifilm reasonably determines that it will be unable to initiate the replacement of the Non-Conforming GMP Product with Conforming GMP Product within the period specified in
Section 1(g)(iv)(1) above (which determination shall be promptly notified to Alder), or (B) the Product manufactured under Section 1(g)(iv)(1) is Non-Conforming GMP Product and the non-conformity was caused by any Fujifilm Factor(s),
then, in either case, at Alder’s option: 

  

	 	(i)	In the case of Section 1(g)(iv)(2)(A), Alder may cancel any such replacement [***], and, in addition, in the case of Section 1(g)(iv)(2)(A) or (B), Alder may issue instructions to Fujifilm for, at Alder’s
option, a payment to Alder of [***] and any other part of the Program that is invalid as a result of the Non-Conformity; Alder [***]; if Alder issues instructions [***], Fujifilm shall issue the payment/credit within [***] of receipt of the
payment/credit instructions; or 

  

	 	(ii)	Alder may issue instructions to Fujifilm for replacement, at a date mutually agreed to by the Parties, under Section 1(g)(iv)(1), and Fujifilm shall proceed accordingly. 

 

	 	(3)	For clarity, in addition, and if applicable, Fujifilm shall either, at Fujifilm’s option, [***], to the extent that the life span of such Consumable has been shortened or if such Consumable has been rendered
unusable. 

  

	 	h)	Except for the indemnities provided in this Agreement and except for any other rights or remedies expressly set forth in this Agreement (including, for example, its termination rights, and its right to [***]), the
remedies set out in Section 1(g) shall be Alder’s sole remedies against Fujifilm for any Non-Conforming GMP Batch caused by or arising as a result of a Fujifilm Factor. 

 

	 	i)	 if the parties do not agree on Fujifilm’s findings in the Disposition Package, and, in particular, with Fujifilm’s determination of
conformity or non-conformity, or on the cause of non-conformity, the matter shall be [***] in accordance with this Agreement and the Quality Agreement. If the parties agree to [***] additional testing or analysis of samples, Fujifilm [***] shall
perform the testing and analysis activities. The costs of such [***] shall be [***]; provided, however, that if [***] is the 

  
 7 

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

	 	
prevailing party, [***] shall [***] for [***]. The decision [***] shall be in writing [***]. For the avoidance of doubt, the Parties will follow Fujifilm quality procedures and cGMP while
accepting or rejecting the disputed Batch. 

  

	 	j)	Unless Alder requests delivery of Non-Conforming GMP Product (for clarity, the Parties acknowledge that any such delivery would be subject to applicable Legal Requirements), Fujifilm shall dispose of Non-Conforming GMP
Product in accordance with all applicable Legal Requirements, [***] if the non-conformity was caused by any Fujifilm Factor(s) and [***]. 

  

	 	k)	Alder may cancel one or more Batches comprising a Manufacturing Stage of a Program and, if a Batch Cancellation Fee is applicable under the terms of this Agreement and the related Statement of Work, [***] in
consideration for technical consultancy in relation to such cancellation. If Alder cancels all of the Batches in a Program, the applicable Program shall be deemed to have been terminated by Alder for convenience under Section 20(b), unless the
parties otherwise agree in writing, and [***] may be applicable under the terms of this Agreement and the related Statement of Work, in which case [***] in consideration for technical consultancy in relation to such cancellation. 

 

	 	l)	For each GMP Batch, the Parties will mutually agree on a “Batch Commencement Date” for the Batch (which date may be changed from time to time by mutual agreement of the Parties). The Batch Commencement Date
will be used to determine whether [***] payable and, if so, [***]. If a [***] is triggered, Fujifilm shall [***] mitigate its loss in this regard, and the parties shall, acting reasonably and in good faith, negotiate [***]. 

 

	 	m)	Alder may, in writing, request changes within the general scope of a Program, and, if such change increases or decreases the cost or time required to perform a Program, [***], to reflect the increase or decrease, and
the Parties shall enter into a PAO to amend the Statement of Work accordingly. 

 Section 2. 

Alder Deliverables 
  

	 	a)	Under each Statement of Work, the Parties will specify with particularity the Alder Deliverables (including any Process Consumables) that are to be provided by Alder for the related Program, and Alder will timely
provide Fujifilm with the applicable Alder Deliverables (as listed in the applicable SoW). Failure by Alder to provide Alder Deliverables within the timeframe set forth in the applicable SoW may cause an increase in the cost or time required to
perform a Program, and, if so, [***], to reflect the increase or decrease, and shall enter into a Program Amendment Order in accordance with Section 6 of this Agreement. 

 

	 	b)	 Title to Alder Deliverables shall remain with Alder. [***]. Fujifilm shall not sell, pledge, hypothecate, or otherwise transfer any interest in Alder
Deliverables. Fujifilm shall not permit access to Alder Deliverables except to persons who have a need to access in order to perform their duties in carrying out Fujifilm’s 

  
 8 

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

	 	
obligations under this Agreement and shall not part with possession of Alder Deliverables except to Affiliates and other approved subcontractors who have a need to possess in order to perform
their duties under this Agreement. Fujifilm shall use Alder Deliverables solely for purposes of performing the applicable Program. Fujifilm shall provide safe and secure storage conditions for Alder Deliverables and protect them from damage and loss
while they are at Fujifilm’s location. 

  

	 	c)	Fujifilm shall timely procure, all Process Consumables (except Process Consumables to be provided by Alder), subject to reimbursement in accordance with the terms of this Agreement and the related Statement of Work.
Fujifilm shall maintain, store and perform testing and evaluation of all Consumables (including Alder-provided Process Consumables), as required by the applicable specifications and cGMP and otherwise in accordance with the Quality Agreement and
applicable SOPs. Fujifilm shall use Process Consumables procured for the Programs or provided by Alder for the Programs solely to perform the Programs. Consumables may be subject to a mutually agreed markup, as set out in Section 5(a) of this
Agreement or as defined in the applicable Statement of Work. 

 Section 3. 

Compliance with Government Regulations 
  

	 	a)	Fujifilm shall perform each Program in a timely and diligently manner; in accordance with the terms and conditions of this Agreement, the applicable SoW and the Quality Agreement; in compliance with all applicable Legal
Requirements, including cGMP (as applicable); in compliance with standard operating procedures and protocols already in place at Fujifilm or as agreed upon by the Parties from time to time; and in compliance with all reasonable written directions
and requests of Alder. Fujifilm shall manufacture GMP Product in compliance with the Process Specification, cGMP and all other applicable Legal Requirements. Fujifilm shall use the applicable Facility to perform each Program, and shall not use a
different facility without the prior written consent of Alder. Fujifilm warrants [***]. This clause is a material clause of this Agreement, and Fujifilm shall promptly notify Alder if it becomes of aware of [***]. 

 

	 	b)	Alder acknowledges that Fujifilm has consulted with Alder in designing each Program in a manner consistent with current U.S. and European regulatory guidelines. Notwithstanding the foregoing, while Fujifilm [***],
Fujifilm [***]. Alder shall have responsibility for determining [***]. The foregoing shall not be construed in derogation of Fujifilm’s obligations set forth in Section 3(a) above. 

 

	 	c)	 Should any applicable Legal Requirements change, Fujifilm will [***] satisfy the new requirements. In the event that compliance with such new Legal
Requirements specifically pertaining to Alder’s Product increases or decreases the cost or time required to perform each Program, the Parties shall negotiate an equitable adjustment in the price or schedule, or both, to reflect the

  
 9 

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

	 	
increase or decrease, and the Parties shall enter into a Program Amendment Order, as herein after defined, in accordance with Section 6 of this Agreement. Changes to Fujifilm’s facility
to entitle it to operate as [***]. 

  

	 	d)	in the event of a conflict between or among any of the standards set forth in this Section 3, Fujifilm shall comply with the most stringent standard which is permitted by law; in the event of a conflict in
Applicable Law, the Parties shall agree on which Applicable Law shall be followed by Fujifilm in its performance of each Program to comply with regulatory requirements and advance the applicable Program. 

 

	 	e)	Alder shall notify Fujifilm promptly if any Product is the subject of a recall, withdrawal, field alert or similar action (collectively a “Recall”), and provide Fujifilm with a copy of all documents relating
to such Recall. Fujifilm shall reasonably cooperate with Alder in connection with any Recall, [***]. Alder shall [***], and provided further than Alder [***]. For clarity, [***]. 

Section 4. 
 Facility Visits; Quality Agreement

  

	 	a)	[***] Alder may carry out one cGMP audit [***], and additional for-cause audits, in accordance with the provisions of the Quality Agreement. [***] audits (other than “for cause” audits) may be carried out
subject to [***] and subject to [***]. In addition, Alder may be on-site at the Facility while active production is occurring, in accordance with the provisions of the Quality Agreement. The full terms and conditions of Alder audits and other visits
are provided in the Quality Agreement. 

  

	 	b)	As soon as possible following execution of this Agreement, the Parties shall execute the Quality Agreement. 

  

	 	c)	Upon request, Fujifilm shall provide Alder [***] with the executed batch record for each GMP Batch, in Fujifilm’s standard format or in such other format as may be agreed by the Parties. in addition, Fujifilm shall
allow Alder to inspect the following at the Facility and, from the time of manufacture and for at least [***] thereafter, via a web-based portal or other agreed method: copies of applicable Batch Records and other related documentation, data and
analytical records, including deviations, discrepancies, out-of-specifications, failures, investigations, and batch-specific environmental monitoring data, water (USP and WFI) and testing data, and all other documentation reasonably requested by
Alder related to such Batch, including process data. Fujifilm shall retain and maintain such manufacturing data and documentation in accordance with and for the time periods required by applicable Legal Requirements, and shall not destroy the same
without the prior written approval of Alder, provided that Fujifilm may destroy the same if Fujifilm has used Commercially Reasonable Efforts to obtain instructions from Alder and Alder has failed to respond of [***]. 

  
 10 

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 Section 5. 

Compensation 
  

	 	a)	Each Statement of Work will list in the Program Price and Payment Schedule the research and development and technical consultancy fees for the related Program. In consideration of the research and development and
technical consultancy activities performed in accordance with this Agreement, Alder shall make the payments set forth in the Program Price and Payment Schedule when due. Fujifilm will list the [***], and Fujifilm shall provide [***]. Following
[***], Fujifilm shall [***], and will [***]. Alder agrees to pay [***] for the Process Consumables purchased for the Program [***], which [***] of [***] (except in the case of chromatography resins, in respect of which the [***]. Unless otherwise
specified in the applicable SoW, these amounts will be invoiced [***]. Fujifilm shall [***] purchase Process Consumables [***]. Ownership of such Process Consumables shall be as specified in the applicable SoW. 

 

	 	b)	Fujifilm shall issue invoices for the sums due under this Agreement as such sums fall due consistent with the Program Price and Payment Schedule and shall send the invoices electronically to Alder at
accounting@alderbio.com or such other email address as Alder may provide, and Alder shall pay amounts due [***] of receipt of the relevant invoice. Late payments are subject to an interest charge of [***]. Unless within [***] of the date of receipt
of an invoice, Alder has advised Fujifilm in good faith and in writing the specific basis for disputing an invoice, failure to pay an invoice within [***] from the date of invoice may [***] constitute a material breach of this Agreement. Invoices
issued for Product that is the subject of a non-conformity investigation or dispute shall not be due [***] after the matter has been resolved. Invoices will include a summary of activities completed during the invoice period, including activities
completed and an indication of Process Consumables purchased. 

  

	 	c)	Alder hereby [***] in [***], while it remains [***]. 

 Section 6. 

Program Amendment Orders 
  

	 	a)	 Each Statement of Work will contain certain key assumptions which need to be met in order for Fujifilm to carry out the relevant Program within the
total budget for the Program specified in the Program Price and Payment Schedule, the individual budget components and the estimated durations specified in the SoW, which assumptions may include general and Program specific assumptions, as well as
the accuracy, timeliness and completeness of Alder’s Deliverables. The assumptions may relate to the Program design and objectives, manpower requirements, timing, capital expenditure requirements, if any, and other matters relating to the
completion of the Program, all as set forth in the SoW (“Program Assumptions”). Fujifilm also assumes that Alder will cooperate and perform its obligations under this Agreement and SoW in a timely manner, that no force majeure event
described in Section 17 will occur, and that there will be no changes to any applicable laws, rules or regulations that will have a material effect on the cost or time required to perform the related Program (the foregoing assumptions together
with the Program Assumptions, 

  
 11 

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

	 	
collectively, the “Assumptions”). If actual circumstances materially differ from the Assumptions set out in the relevant Statement of Work or as otherwise referred to in this
Section 6(a), thereby causing an increase or decrease in the cost or time required to perform the Program, the Parties [***] to reflect the increase or decrease, and the Parties shall enter into a PAO to amend the Statement of Work accordingly.
Fujifilm and Alder each represent [***]; provided, however, that Alder [***]. 

  

	 	b)	In the event a modification contemplated by Section 6(a) (each, a “Modification”) is requested by Alder or is identified by Alder or by Fujifilm, the identifying Party shall notify the other Party as soon
as is reasonably possible. Fujifilm shall provide Alder with a draft PAO containing an estimate of the required Modifications to the Program budget, activities and/or estimated duration as specified in the SoW (“Program Amendment Order”)
[***] of receiving such notice or providing such notice to Alder. Alder shall respond in writing to such Program Amendment Order [***] of receiving such Program Amendment Order indicating whether or not it approves the proposed Program Amendment
Order. Alder shall be deemed to have disapproved the Program Amendment Order if Fujifilm does not receive a written indication from Alder during such [***] period. If Alder does not approve such Program Amendment Order, then Alder and Fujifilm shall
[***] agree on a Program Amendment Order that is [***]. If practicable. Fujifilm shall continue work on the Program during any such negotiations, but shall not commence work with respect to the Program Amendment Order unless authorized in writing by
Alder. If a Modification results in a Program Amendment Order [***] after issuance of the relevant Program Amendment Order and [***] then Fujifilm shall, if reasonably possible, perform the SoW as modified by previously executed Program Amendment
Orders, if any, without regard to the unresolved Program Amendment Order; provided, however, that the estimated timelines shall be adjusted to reflect any delay during the negotiation period. In the event that in Fujifilm’s reasonable judgment
such performance in not possible in accordance with the current SoW and Program Price and Payment Schedule, then Fujifilm shall provide written notice to Alder of its inability to perform in the absence of an agreed upon Program Amendment Order (the
“Impasse Notice”). Upon issuance of an Impasse Notice, either Party shall have the option to terminate this Agreement or the Program affected by such Program Amendment Order within [***] following such Impasse Notice. For clarity,
following issuance of an Impasse Notice, either Party may initiate the arbitration procedures set forth in Section 14 [***], whether or not the Agreement or a Program has been terminated and if such termination has occurred, irrespective of
whether such Party was the terminating Party. In determining [***], if any, the arbitrator(s) shall consider [***] and, if so, [***]. 

Section 7. 
 Confidential Information/Legal
Proceedings 
  

	 	a)	 Except as otherwise expressly permitted under this Agreement, Fujifilm shall not disclose, without Alder’s written permission, any confidential
information pertaining to any Program or any other proprietary, confidential and/or trade secret information or materials disclosed to, delivered to or obtained by Fujifilm under or in anticipation of this Agreement or the Prior Agreement,
including, but not limited to, Alder 

  
 12 

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

	 	
Technology (all of the foregoing, “Alder’s Confidential Information”) unless: (i) such disclosure is to an Affiliate of Fujifilm that is under an obligation of confidentiality
and non-use and inventions to Fujifilm no less burdensome than such obligations of Fujifilm to Alder and for whose actions Fujifilm shall remain liable, and who has a need to know the Confidential Information to perform the applicable Program or
otherwise as necessary to perform Fujifilm’s obligations or exercise its rights under this Agreement (ii) such information is or becomes publicly available through no fault of Fujifilm and through no other breach of an obligation of
confidentiality owed to Alder or its Affiliate(s); (iii) such information is disclosed to Fujifilm on a non-confidential basis by a third party entitled to disclose it and who did not acquire it directly or indirectly from Alder; (iv) such
information is already known to Fujifilm on a non-confidential basis as shown by its prior written records, and was not acquired directly or indirectly from Alder; or, (v) such disclosure is required by any law, rule, regulation, order
decision, decree, subpoena or other legal process to be disclosed. If such disclosure is required by legal process, Fujifilm will make all reasonable efforts to notify Alder of this request promptly prior to any disclosure to permit Alder to oppose
such disclosure by appropriate legal action. Fujifilm shall use reasonable precautions to protect the confidentiality of Alder’s Confidential Information comparable to precautions taken to protect its own proprietary information including
restricting access to such information to such of its employees as are bound to keep such information confidential and need to have such access for the purpose of this Agreement. Without limitation, Alder Technology, Alder Process Inventions,
Disposition Packages, Product Process, Product Inventions, Product Specification, and Work Output, and (other than and not including any of Fujifilm’s Confidential Information or Fujifilm Process Inventions) the material and information
comprising, contained in or relating to any of the foregoing, shall be deemed Alder’s Confidential Information, regardless of whether marked or confirmed as confidential, and as to which Alder shall be deemed the disclosing Party.

  

	 	b)	Except as otherwise expressly permitted under this Agreement, Alder shall not disclose, without Fujifilm’s written permission, any proprietary, confidential and/or trade secret information of Fujifilm disclosed to,
delivered to or obtained by Alder under this Agreement or the Prior Agreement (all of the foregoing, “Fujifilm’s Confidential Information”) unless: (i) such disclosure is to an Affiliate of Alder that is under an obligation of
confidentiality and non-use and inventions to Alder no less burdensome than such obligations of Alder to Fujifilm and for whose actions Alder shall remain liable, and who has a need to know the Confidential Information to perform the applicable
Program or otherwise as necessary to perform Alder’s obligations or exercise its rights under this Agreement; (ii) such information is or becomes publicly available through no fault of Alder and through no other breach of an obligation of
confidentiality owed to Fujifilm or its Affiliate(s); (iii) such information is disclosed to Alder on a non-confidential basis by a third party entitled to disclose it and who did not acquire it directly or indirectly from Fujifilm;
(iv) such information is already known to Alder on a non-confidential basis as shown by its prior written records, and was not acquired directly or indirectly from Fujifilm; or, (v) such disclosure is required by any law, rule, regulation,
order decision, decree, subpoena or other legal process to be disclosed. If such disclosure is required by legal process, Alder will make all reasonable efforts to notify Fujifilm of this request promptly prior to any disclosure to permit
Fujifilm to oppose such disclosure by appropriate legal action. Alder shall use reasonable precautions to protect the confidentiality of Fujifilm’s Confidential Information comparable to precautions taken to protect its own proprietary
information including restricting access to such information to such of its employees as are bound to keep such information confidential and need to have such access for the purpose of this Agreement. 

 

	 	c)	If a Party shall be obliged to provide testimony or records containing Confidential Information of the other in any legal or administrative proceeding, then the Party to whom the Confidential Information belongs shall
reimburse the other Party for its [***]. This clause shall not apply to disputes between or among the Parties. 

  
 13 

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

	 	d)	For each of the Parties, “Confidential Information” shall mean and include without limitation such types of information as: inventions, methods, plans, processes, specifications, characteristics, raw data,
analyses, equipment design, trade secrets, costs, marketing, sales, and performance information, including patents and patent applications, grant applications, notes, and memoranda, whether in writing or presented, stored or maintained
electronically, magnetically or by other means, which are directly or indirectly disclosed to, delivered to or obtained by the recipient Party pursuant to this Agreement or the Prior Agreement, or of which a recipient Party may become aware of
through the presence of its employees or agents at another Party’s offices or facilities. Each Party will use commercially reasonable efforts to identify to the others, orally or in writing, the confidential nature of its Confidential
Information, and, if disclosed orally, to confirm the same in writing within [***] following the first disclosure of such Confidential Information to the receiving Party, but the failure to do so shall not relieve the Party receiving the information
or materials of its obligation to protect the same where the cirucmstances of the disclosure and the nature of the information or materials othewise give the receiving Party reason to know of the confidential nature of such information or materials.

  

	 	e)	Each receiving Party agrees to use the other Party’s Confidential Information solely to perform its obligations and exercise its rights under this Agreement. 

 

	 	f)	The receiving Party may disclose Confidential Information to or receive Confidential Information through its Affiliates, employees and agents who need to know the Confidential Information to perform the applicable
Program or otherwise as necessary to perform obligations or exercise rights under this Agreement, provided that the receiving Party shall procure that prior to disclosure of Confidential Information each Affiliate, employee or agent to whom
Confidential Information is to be disclosed is apprised of the confidential nature of the information or material, made aware of the confidentiality, non-use and inventions obligations contained in this Agreement, and agrees to be subject to and is
bound by confidentiality, non-use and inventions obligations no less onerous than those contained in this Agreement. Any breaches of the obligations contained in this Agreement by such Affiliate(s), employee(s) or agent(s) shall be treated as a
breach of such obligations by the receiving Party. 

 Section 8. 

Work Output 
  

	 	a)	All reports specified in the SoW and other cGMP documentation (“Work Output”) will be prepared using Fujifilm’s standard format(s) unless otherwise specified in the SoW. 

 

	 	b)	 Alder will be supplied with copies of Work Output generated as a result of the Program as set forth in the applicable SoW or Quality Agreement. All
Work Output and agreed Product samples will be archived by Fujifilm for a period of [***] following completion of the Program unless otherwise defined by the Program or required by applicable U.S. and European laws or regulations. [***] after
completion of the Program, Work Output and Product samples will be sent to Alder and a [***]. Alder may elect to have the materials retained in the Fujifilm archives for an additional period of time [***]. If Alder chooses to have Fujifilm dispose
of Work Output and Product samples, [***]. Notwithstanding the foregoing, Fujifilm will continue to retain such written materials and Product samples as required 

  
 14 

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

	 	
by regulations and as may be required by law, pertaining to such activities as well as for archival purposes. All Work Output shall be owned by Alder and shall be its Confidential Information.

 Section 9. 
 Inventions and Patents

  

	 	a)	Fujifilm on behalf of itself, its Affiliates and its subcontractors; and their respective employees and agents, hereby irrevocably assigns and shall assign, at no cost, to Alder: 

 

	 	(i)	any invention or discovery that is a modification, addition, improvement, adaptation, enhancement, derivative, variant, or progeny to any Alder Technology or to a Product or to a use of a Product, in each of the
foregoing cases that is not included within Alder Process Inventions, whether conceived, created, authored, or reduced to practice solely by one Party (or its Affiliate or subcontractor) and its employees or agents, or jointly by both Fujifilm (or
its Affiliate or subcontractor) and Alder (or its Affiliate or subcontractor) and their respective employees or agents, whether or not patentable, arising as a result of performing a Program under this Agreement or through other use of or reference
to Alder Technology or other Confidential Information of Alder (all of the foregoing, “Product Inventions”), and 

  

	 	(ii)	any inventive manufacturing or analytical methods and processes, in each of the foregoing cases that are not included within Fujifilm Process Inventions, whether conceived, created, authored, or reduced to practice
solely by one Party (or its Affiliate or subcontractor) and its employees or agents, or jointly by both Fujifilm (or its Affiliate or subcontractor) and Alder (or its Affiliate or subcontractor) and their respective employees or agents, whether or
not patentable, arising as a result of performing a Program under this Agreement or though other use of or reference to Alder Technology or other Confidential Information of Alder (all of the foregoing, “Alder Process Inventions”).

 Fujifilm shall promptly disclose to Alder all Product Inventions and Alder Process Inventions. At Alder’s request
[***], Fujifilm will execute any and all applications, assignments or other instruments and give testimony which shall be necessary to apply for and obtain Letters of Patent of the US or of any foreign country with respect to Product Inventions and
Alder Process Inventions, and perfect Alder’s title thereto, and Alder [***]. Fujifilm warrants that all Product Inventions and Alder Process-Inventions made in whole or in party by Fujifilm (or its Affiliate or subcontractor) and any employees
(subject to any applicable law that protects employee inventors) or agents are [***]. With respect to Product Inventions and Alder Process Inventions assigned pursuant to this section, Alder hereby grants to Fujifilm a [***] license, to the extent
necessary for Fujifilm to perform its obligations under this Agreement, for the [***] purpose of performing the applicable Program, for the term of this Agreement. The Alder Technology shall [***]. For the avoidance of doubt, “Alder
Technology” shall not include, for purposes of this Agreement, any information that, at the time of disclosure to, delivery to or acquisition by Fujifilm, was either (i) in the public domain, or (ii) as shown by

  
 15 

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 
Fujifilm’s prior written records, was already known by Fujifilm on a non-confidential basis, and was not acquired directly or indirectly from Alder or conceived, created, authored, or
reduced to practice by Fujifilm under this Agreement or the Prior Agreement, or (iii) subsequently enters the public domain through no fault of Fujifilm and through no other breach of an obligation of confidentiality owed to Alder or its
Affiliate(s). Notwithstanding anything to the contrary in the immediately preceding sentence, information that is the subject of pending patent applications or issued patents of Alder or its Affiliates or their respective licensors shall not be
deemed to be in the “public domain” by virtue thereof. 
  

	 	b)	Fujifilm [***] to any invention or discovery, whether or not patentable, that meets all of the following conditions: (i) it relates to manufacturing or analytical methods and processes, (ii) it is conceived,
created, authored, or reduced to practice [***] by Fujifilm and its employees or agents or jointly by both Fujifilm (or its Affiliate or subcontractor) and Alder (or its Affiliate or subcontractor) and their respective employees or agents in
connection with the Program, (iii) is generally applicable to the development or manufacture of biological products, (iv) does not require the use of or reference to a Product or any element of the Alder Technology, and (v) when used,
does not reveal or disclose any of Alder’s Confidential Information, Alder Technology, or Product(s) (all of the foregoing, “Fujifilm Process Inventions”). [***] Alder will execute any and all applications, assignments or other
instruments and give testimony which shall be necessary to apply for and obtain Letters of Patent of the US or of any foreign country with respect to the Fujifilm Process Inventions and [***], and Fujifilm shall compensate Alder for the time devoted
to such activities and reimburse it for [***]. Fujifilm hereby grants to Alder a [***] license [***] to [***] Products manufactured under this Agreement [***]. Pre-existing Fujifilm inventions and know-how shall remain the sole and exclusive
property of Fujifilm, and shall be subject only to such licenses as may be expressly set forth in this Agreement. 

  

	 	c)	The Parties intend that the Process shall be fully portable by Alder, [***]. If requested by Alder, Fujifilm shall [***] provide technology transfer services in support of the transfer to Alder (or its designee) of the
Process for the Product and certain manufacturing technology and know-how related thereto (the “Technology Transfer”), such as (i) providing additional copies of pertinent information necessary to manufacture the Product and/or
to support regulatory filings for the Product, including analytical testing methods, protocols, process descriptions, batch records, manufacturing documentation, raw data, and other process and manufacturing data and documentation; and
(ii) providing Alder or its designee with access to Fujifilm employees with expertise in manufacturing to answer questions related to such Technology Transfer. The parties agree that this provision assumes that the Programs carried out for
Alder will not involve the use of any Intellectual Property to which Fujifilm would normally grant access to under a commercial licence. in the event that a Program would require use of any such Intellectual Property, Fujifilm will notify Alder in
advance and shall only use such Intellectual Property in a Program with Alder’s written consent. The Statement of Work applicable to such Program shall identify such Intellectual Property and shall prominently describe in the main body of the
Statement of Work the agreed variations to this Section 9. 

  
 16 

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 Section 10. 

Independent Contractor 
 Fujifilm shall perform each
Program as an independent contractor of Alder, and Fujifilm shall have complete and exclusive control over its facilities, equipment, employees and agents. The provisions of this Agreement shall not be construed to establish any form of partnership,
agency or other joint venture of any kind between Fujifilm and Alder, nor to constitute either Party as the agent, employee or legal representative of the other. All persons furnished by either Party to accomplish the intent of this Agreement shall
be considered solely as the furnishing Party’s employees or agents and the furnishing Party shall be solely responsible for compliance with all laws, rules and regulations involving, but not limited to, employment of labor, hours of labor,
working conditions, workers’ compensation, payment of wages, and withholding and payment of applicable taxes, including, but not limited to income taxes, unemployment taxes, and social security taxes. No Party shall hold itself out to any third
party as purporting to act on behalf of, or serving as the agent of, any other Party. 
 Section 11. 

Insurance 
  

	 	a)	Fujifilm shall secure and maintain in full force and effect throughout the performance of the Programs and through the date that is [***] after the expiration date of all Product manufactured under this Agreement,
policies of insurance appropriate to the conduct of that Party’s business, including without limitation: (a) workmen’s compensation (or United Kingdom equivalent), (b) commercial general liability, (c) public and product
liability, and contractual liability, in each case having policy limits, deductibles and other terms appropriate to the conduct of Fujifilm’s business [***]. 

 

	 	b)	Alder shall secure and maintain in full force and effect throughout the performance of the Programs and through the date that is [***] after the expiration date of all Product manufactured under this Agreement, policies
of insurance appropriate to the conduct of that Party’s business, including without limitation: for (a) commercial general liability and (b) clinical trials/product liability, in each case having policy limits, deductibles and other
terms appropriate to the conduct of Alder’s business [***]. 

 Section 12. 

Delivery and [***] 
  

	 	a)	Delivery of all material manufactured for or purchased by Alder under this Agreement, including any quantity of Product manufactured during a Program or Process Consumables purchased by Alder under an SoW, will be made
Ex Works, the Facility (Incoterms 2010), when Fujifilm notifies Alder that such material is available for collection and places Product at the disposal of Alder at the Facility, or, in the case of any Batch produced during a manufacturing stage of a
Program, either [***] following notification by Fujifilm that Fujifilm has completed Disposition in respect of such Batch and has made such material available for collection, or [***], whichever occurs first. Unless otherwise agreed by the Parties,
Fujifilm shall deliver a Certificate of Analysis, if applicable, not later than the date of delivery. Fujifilm shall package and label Product for delivery in accordance with the Product Specification, standard operating procedures and all
applicable Legal Requirements. Risk in and title to all material manufactured for or purchased by Alder under this Agreement [***]. Fujifilm will co-operate with Alder’s chosen shipper/supplier with regard to achieving timely and efficient
transport matters. 

  

	 	b)	 Alder shall have the option, [***], to request that Fujifilm [***], and may also request that, [***], Fujifilm [***], in each case [***]. In the
absence of exercise of such option and agreement on the terms of such [***], Fujifilm shall not be obliged to [***]. Prior to completion of the applicable Program, Alder shall notify Fujifilm which [***], and, if

  
 17 

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

	 	
Alder does not notify Fujifilm [***], then Fujifilm shall request instructions from Alder and shall, in accordance with such instructions, [***]. Nothing in this paragraph shall be construed in
derogation of Fujifilm’s obligations with respect to [***]. 

  

	 	c)	Fujifilm shall provide reasonable assistance to Alder as may be necessary for complying with import, export, and customs laws, regulations and like requirements, as applicable to the shipment of Product, the cell banks,
and samples (including in-process samples) of the Product, etc., including issuing any documentation that may be required to be issued by Fujifilm by law or regulation. Without limitation, Fujifilm and Alder will cooperate and provide such
assistance to each other as may be reasonably necessary to permit the export of Product from England into other countries, and Fujifilm shall provide reasonable assistance to Alder as may be necessary for obtaining permits from the United States
Department of Agriculture for the shipment of Product from England to the USA for toxicology studies. Alder shall be responsible [***]. 

Section 13. 
 Default/Limitation of Warranty

  

	 	a)	If Fujifilm is in default of any material obligation under this Agreement or a Statement of Work, then Alder shall promptly notify Fujifilm in writing of any such default. Fujifilm shall have a period of [***] from the
date of receipt of such notice within which to cure such default (if such breach is capable of remedy and provided that Fujifilm has commenced a cure within the [***] period and is diligently pursuing efforts to cure such breach); provided that if
Fujifilm falls to cure such breach within the specified cure period, this Agreement or Statement of Work, as applicable, may, at Alder’s option, immediately terminate. For clarity, the Parties agree that if Alder exercises its right to
terminate this Agreement under this clause, the termination will be effective with respect to both of the Fujifilm Parties. 

  

	 	b)	If Alder is in default of any material obligation under this Agreement or a Statement of Work, Fujifilm shall promptly notify Alder in writing of any such default. Alder shall have a period of [***] from the date of
receipt of such notice within which to cure such default (if such breach is capable of remedy and provided that Alder has commenced a cure within the [***] period and is diligently pursuing efforts to cure such breach); provided that if Alder
fails to cure such breath within the specified cure period, this Agreement or Statement of Work, as applicable, may, at Fujifilm’s option, immediately terminate. 

 

	 	c)	 Subject to Section 13(e) and the last sentence of this paragraph, UNDER NO CIRCUMSTANCES SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR
ANY INCIDENTAL, INDIRECT, CONSEQUENTIAL OR SPECIAL DAMAGES ARISING IN CONNECTION WITH THE DEFAULT OR BREACH OF ANY OBLIGATION OF THE OTHER PARTY UNDER THIS AGREEMENT, THE STATEMENT OF WORK OR ANY DOCUMENTS OR APPENDICES RELATED

  
 18 

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

	 	
THERETO. Subject to Section 13(e) and the last sentence of this paragraph, [***]. This Section 13(c) shall not limit Fujifilm’s obligations under Section 1(g) or
Section 3(e). 

  

	 	d)	THE WARRANTIES EXPRESSLY SET FORTH IN THIS AGREEMENT ARE IN LIEU OF ALL OTHER WARRANTIES, AND, EXCEPT FOR THE WARRANTIES EXPRESSLY SET FORTH IN THIS AGREEMENT, INCLUDING THE WARRANTIES IF ANY THAT MAY BE SET
FORTH IN THE STATEMENTS OF WORK, (I) NEITHER PARTY PROVIDES TO THE OTHER PARTY HERETO ANY WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE MATERIALS AND SERVICES PROVIDED HEREUNDER, (II) ALL SUCH WARRANTIES, EXPRESS OR IMPLIED, INCLUDING
WITHOUT LIMITATION ANY IMPLIED WARRANTIES OR MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE ARE WAIVED AND (III) FUJIFILM MAKES NO WARRANTIES THAT THE EXECUTION OF THE SOW WILL RESULT IN ANY SPECIFIC QUANTITY OR QUALITY OF PRODUCT OR THAT
FUJIFILM WILL HAVE AVAILABLE CAPACITY FOR FUTURE PRODUCTION OF PRODUCT. 

  

	 	e)	The limitations of liability and disclaimers in Section 13(c) and Section 13(d) shall [***]. 

Section 14. 
 Dispute Resolution 

 

	 	a)	In the event any dispute shall arise between Alder and Fujifilm with respect to any of the terms and conditions of this Agreement or a Program, then senior executives of Alder and Fujifilm shall meet as promptly as
practicable after notice of such dispute to resolve in good faith such dispute. 

  

	 	b)	If Alder and Fujifilm are unable to satisfactorily resolve the dispute within [***] following referral to the senior executives, then either Party may request that the dispute be [***] arbitrator in accordance with this
Section 14. The arbitration will be [***], and except as noted below, shall be conducted [***] by a neutral arbitrator possessing demonstrated qualifications in a field relevant to the dispute who is agreeable to both Parties. If the Parties do
not agree on an arbitrator [***], [***] shall appoint an arbitrator to hear the case [***]. The arbitrator shall [***] or to [***] and shall [***]. The Parties intend that any arbitration proceedings [***], and the Parties [***], any information
submitted during the arbitration, any documents submitted in connection with it, any oral submissions or testimony, transcripts, or any award [***]. No Party shall be precluded from seeking preliminary, provisional, interim or conservatory measure
or taking such interim formal steps as may be considered necessary to protect such Party’s position at any time either before or after the tribunal has been appointed or while the procedures referred to in this Section are pursued.

  

	 	c)	Any decision by the arbitrator shall be [***] and may be entered [***] in any court having jurisdiction. The cost of any arbitration proceeding shall be [***]. The arbitrator shall render his final decision in writing
to the Parties. 

  
 19 

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 Section 15. 

Limitation and Indemnification 
  

	 	15.1	Indemnification by Fujifilm. Subject to and except to the extent of any indemnification from Alder pursuant to Section 15.2 below, Fujifilm shall defend, indemnify and hold harmless each of Alder and its Affiliates
and their respective directors, officers, employees and agents and the successors and assigns of any of the foregoing (all of the foregoing, the “Alder Indemnitees”) from and against all claims made or lawsuits brought by a third party,
[***] (collectively “Claims and Losses”), to the extent such Claims and Losses arise out of: (a) breach of this Agreement by Fujifilm or any other Fujifilm Indemnitee, (b) the negligent or more culpable acts or omissions of
Fujifilm or any other Fujifilm Indemnitee, or (c) any claims alleging that Alder’s use of Fujifilm Intellectual Property for permitted purposes in the performance of a Program under and in accordance with this Agreement (excluding use
thereof in combination with Alder Intellectual Property for permitted purposes under and in accordance with this Agreement, if there would have been no infringement absent the combination) infringes any valid Intellectual Property rights vested in a
third party. 

  

	 	15.2	Indemnification by Alder. Subject to and except to the extent of any indemnification from Fujifilm pursuant to Section 15.1 above, Alder shall defend, indemnify and hold harmless each of Fujifilm and its Affiliates
and subcontractors and the respective directors, officers, employees and agents and the successors and assigns of any of the foregoing (all of the foregoing, the “Fujifilm Indemnitees”) from and against all Claims and Losses to the extent
such Claims and Losses arise out of: (a) breach of this Agreement by Alder or any other Alder Indemnitee, (b) the negligent or more culpable acts or omissions of Alder or any other Alder Indemnitee; (c) any claims alleging
Fujifilm’s use of the Alder Intellectual Property for permitted purposes in the performance of a Program under and in accordance with this Agreement (excluding use thereof in combination with Fujifilm Intellectual Property for permitted
purposes under and in accordance with this Agreement, if there would have been no infringement absent the combination) infringes any valid Intellectual Property rights vested in any third party, or (d) [***]; or (e) use or operation of the
Process (or part of the Process) by or on behalf of Alder (other than use or operation by Fujifilm or any other Fujifilm Indemnitee). 

  

	 	15.3	Indemnification Procedure. If a Fujifilm Indemnitee or Alder Indemnitee (the “Indemnitee”) intends to claim indemnification under Section 15.1 or Section 15.2 (as applicable), it shall promptly
notify the other Party (the “Indemnitor”) in writing of such alleged liability. The Indemnitor shall have the right to full control of the defense and settlement thereof with counsel of its choice as long as such counsel is reasonably
acceptable to Indemnitee; provided, however, that any Indemnitee shall have the right to retain its own counsel at its own expense, for any reason, including if representation of any Indemnitee by the counsel retained by the Indemnitor would be

  
 20 

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

	 	
inappropriate due to actual or potential differing interests between such Indemnitee and any other Party reasonably represented by such counsel in such proceeding. The Indemnitee, its employees
and agents, shall cooperate fully with the Indemnitor and its legal representatives in the investigation, defense and settlement of any liability covered by Section 15.1/15.2, provided that no settlement shall include an admission of fault,
liability or a financial obligation on the part of the Indemnified parties without their prior written consent, which consent shall not be withheld or delayed unreasonably. The obligations of the Indemnitor to the Indemnitee under
Section 15.1/15.2 are expressly conditioned on the following: (a) that the Indemnified parties do not make any admission in respect of such claim or suit or take any action prejudicial to the defense of such claim or suit without the prior
written consent of the Indemnitor, which shall not be unreasonably withheld (provided that this condition shall not be treated as breached by any statement properly made by any Party in connection with the operation of its internal complaint
procedures, accident reporting procedures or disciplinary procedures, or where such a statement is required by law); and (b) that the indemnified parties do not enter into any settlement or resolution of such claim or suit or part thereof
without the prior written consent of the Indemnitor, which consent shall not be withheld or delayed unreasonably. The obligations of the Indemnitor to the Indemnitee under Section 15.1/15.2 shall not apply to amounts paid in settlement of any
claim, demand, action or other proceeding if such settlement is effected without the consent of the Indemnitor, which consent shall not be withheld or delayed unreasonably. The failure to deliver written notice to the Indemnitor within a reasonable
time after the commencement of any such action, shall, to the extent prejudicial to its ability and rights to defend or settle such action, relieve the Indemnitor of any obligation to the Indemnitee under Section 15.1/15.2. It is understood
that only Fujifilm and Alder may claim indemnity under Section 15.1/15.2 (on its own behalf or on behalf of its Indemnitees), and other Indemnitees may not directly claim indemnity hereunder. 

Section 16. 
 Representations and Warranties

  

	 	a)	Each Party represents and warrants to the others that it has the full right and authority to enter into this Agreement and to perform in accordance with the terms and conditions set forth herein. Each Party represents
and warrants to the others that neither it nor any of its officers, directors, or its employees performing services under this Agreement [***]. 

  

	 	b)	Each Party represents and warrants to the others that it has obtained and will at all times during the term of this Agreement, hold and comply with all licenses, permits and authorizations necessary to perform this
Agreement as now or hereafter required under any applicable statutes, laws, ordinances, rules and regulations of the United States and any applicable foreign, state, and local governments and governmental entities. 

 

	 	c)	Alder hereby represents and warrants to Fujifilm that it has legal title and/or a valid license to the Alder Technology as it considers necessary to conduct the Programs and [***] the use of its intellectual property,
including Alder Technology, in the performance of the Programs, as presently contemplated and in accordance with the terms of this Agreement, will not violate or infringe on the patents, trademarks, trade names, service marks or copyrights of any
other party. 

  

	 	d)	Fujifilm’s represents that, (i) [***] the use of its intellectual property in the performance of the Programs, as presently contemplated and in accordance with the terms of this Agreement, will not violate or
infringe on the patents, trademarks, trade names, service marks or copyrights of any other party and 

 (ii) it will [***]
ensure that no process modification made pursuant to this Agreement will violate or infringe on the patents, trademarks, trade names, service marks or copyrights of any other party. 

  
 21 

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 Section 17. 

Force Majeure 
 No Party shall be in breach of this
Agreement for any failure to perform its respective obligations under this Agreement if its performance is delayed or prevented by any event beyond such Party’s reasonable control and without the fault or negligence of such Party, which may
include, without limitation, acts of God, fire, explosion, weather, disease, war, insurrection, civil strife, riots, government action, acts of terrorism or power failure, provided that such performance shall be excused only to the extent of and
during such disability. Force majeure shall not include failure of any Product or drug product in clinical trials or failure of any Product or drug product to gain regulatory approval. The Party subject to such event shall promptly notify the other
Party of the occurrence thereof and, if known, the expected duration. Any time specified or estimated for completion of performance in the applicable SoW falling due during or subsequent to the occurrence of any or such events shall be automatically
extended for a period of time to recover from such disability. Fujifilm will promptly notify Alder if, by reason of any of the events referred to herein, Fujifilm is unable to meet any such time for performance specified or estimated in the
applicable SoW. If any part of a Program is invalid as a result of such disability, Fujifilm will, upon written request from Alder, but at Fujifilm’s sole cost and expense, repeat that part of the Program affected by the disability. Without
prejudice to and in addition to any other rights of termination under this Agreement, the non-affected Party may terminate this Agreement or the applicable SoW to the extent that such event continues or will continue for a period of at least [***].
Termination of an SoW or this Agreement as a result of a force majeure event shall take effect as if the SoW or Agreement were terminated under Section 20(b) save that no Cancellation Fee shall be payable. 

Section 18. 
 Allocation of Resources 

If delays in the agreed commencement or performance of a Program occur because of Alder’s request for a delay or its inability to supply Fujifilm by the
deadline set forth in the applicable Statement of Work with agreed Alder Deliverables or any information required to begin or perform the Program, and the delay continues for [***] or more, and Fujifilm wishes to reallocate resources being held for
performance of the Program, it shall advise Alder accordingly. In such event, unless Alder is willing to pay a reasonable amount to Fujifilm to compensate for further delay, Fujifilm may reallocate such resources without incurring liability to
Alder, and Fujifilm shall be relieved of its obligation to perform the Program as set forth in the SoW, except that upon such delay being removed or remedied, Fujifilm will [***] allocate resources to performance of the Program as set forth in the
SoW. Except as expressly set forth in this Agreement, no such delay shall give rise to a right of action or remedy to Fujifilm. 
 Section 19. 

Use of Names 
 No Party may issue any press releases
or other announcements or other form of publicity relating to this Agreement or the activities contemplated hereby or any ancillary matter without the prior written consent of the other Parties. Without limitation, no Party shall use the name of the
other Party or the names of the employees of the other Party in any advertising or sales promotional material or in any publication without prior written permission of such Party. No Party shall disclose to any third party the contents of the
Agreement without the prior written consent of the other Party. Notwithstanding the foregoing to the contrary, each Party shall be entitled to make disclosures as required in connection with regulatory filings, patent filings, or as may otherwise be
required by law, rule or regulation. 

  
 22 

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 Section 20. 

Term/Termination 
  

	 	a)	This Agreement shall take effect on the Effective Date first written above and continue in effect until the earlier of completion of the Programs as acknowledged by the Parties, or termination. 

 

	 	b)	In addition to the termination rights set forth in Section 13 and Section 17, Alder may at any time terminate a Statement of Work or this Agreement prior to completion of the Programs by giving not less than
[***] written notice to Fujifilm. In the event Alder elects to terminate a Statement of Work or this Agreement for convenience under this Section 20(b), or in the event that Fujifilm terminates a Statement of Work or this Agreement pursuant to
Section 13, Alder shall pay Fujifilm [***] following receipt of Fujifilm’s invoice, the following amounts: 

  

	 	(i)	[***]; plus 

  

	 	(ii)	All unpaid costs incurred or committed for non-cancellable Process Consumables, which shall become Alder property; plus 

  

	 	(iii)	The applicable Cancellation Fee, if any. 

  

	 	c)	The termination or expiration of this Agreement for any reason shall not prejudice the acquired rights of any Party under this Agreement, or relieve any Party of its obligation to the other(s) under this Agreement,
including in respect of: (i) confidentiality and non-use; (ii) consents for advertising purposes and publications; (ill) indemnification; (iv) inventions and patents; (v) compensation for services previously performed; and
(vi) dispute resolution. The provisions of Section 1(g), Section 1(h), Section 3(e), Section 4(c), Section 5, Section 7, Section 8(b), Section 9, Section 11, Section 13(c), Section 13(d),
Section 13(e), Section 14, Section 15, Section 19, Section 20 and Section 25 shall survive indefinitely the expiration or termination of this Agreement, as will any other provision that by its intent or meaning should
have validity beyond the expiration or termination of this Agreement. 

  

	 	d)	The termination of this Agreement shall automatically and without further action cause the termination of all Programs and Statements of Work. 

 

	 	e)	Upon the expiration or termination of the Agreement for whatever reason: (1) Fujifilm shall cease all use of and, as directed by Alder, dispose of or return to Alder all information, materials and property of
Alder, and any materials therefrom, and, upon request, shall certify to the foregoing; and Fujifilm shall refund within [***] of the effective date of such expiration or termination all amounts, if any, paid to Fujifilm in excess of amounts owed to
Fujifilm under this Agreement and (2) Alder shall cease all use of and, as directed by Fujifilm, dispose of or return to Alder all information, materials and property of Fujifilm, and, upon request, shall certify to the foregoing; and Alder
shall pay to Fujifilm within [***] of the effective date of such expiration or termination all amounts, if any, owed to Fujifilm under this Agreement, including, for the avoidance of doubt, any amounts payable to Fujifilm on termination under this
Section 20. 

  
 23 

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 Section 21. 

Assignment 
 This Agreement shall not be assigned in
whole or in part by any Party without the prior written consent of the other, which consent shall not be unreasonably withheld or delayed. Any attempt to assign this Agreement without such consent shall be void and of no effect. Notwithstanding the
foregoing, Alder, FDBK or FDBU shall be entitled, without the prior written consent of any other Party, to assign all or a part of its rights under this Agreement to a purchaser of all or substantially all of its assets, and Alder may assign this
Agreement without consent to a third party who has entered into a strategic collaboration agreement or similar agreement with Alder for the development and commercialization of a Product, provided that the assignee agrees in writing to assume all
obligations undertaken by its assignor in this Agreement. No assignment shall relieve the assigning Party of responsibility for the performance of any of its obligations hereunder. The terms of this Agreement shall inure to the benefit of successors
and assigns. 
 Section 22. 
 Notice 

All notices to be given as required in this Agreement shall be in writing and shall be delivered personally, or mailed by a reputable overnight carrier,
postage prepaid, to the Parties at the addresses respectively set forth below or such other addresses as the Parties may respectively designate in writing. Such notice shall be effective on the date received. 

If to Alder: 
 Mark Litton, Ph.D. 

Chief Business Officer 
 Alder Biopharmaceuticals Inc. 

11804 North Creek Parkway South 
 Bothell WA 98011 USA 

P: +1-425-205-2900 
 F: +1-425-205-2901 

with a copy to: 
 Sonya F. Erickson 

Cooley LLP 
 1700 Seventh Avenue, Suite 1900 

Seattle WA 98101 USA 
 P: +1-206-452-8700 

F: +1-206-452-8800 
 If to Fujifilm: 

 

			
	 President
 FUJIFILM Diosynth Biotechnologies
U.S.A., Inc.
 101 J. Morris Commons Lane
 Morrisville, NC
27560
 P: +1-919-337-4404
 F: +1-919-337-0899
	  	 Managing Director
 FUJIFILM Diosynth
Biotechnologies UK Limited
 Belasis Avenue, Billingham
 TS23
1LH, United Kingdom
 F: (+44)(0)1642 364463

		
	 With copies to:
 General Counsel

FUJIFILM Diosynth Biotechnologies
 Belasis Avenue

Billingham, Cleveland, TS 23 1LH, UK
 Facsimile No.: +44 1642
364463
	  	

  
 24 

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

 General Counsel 

FUJIFILM Holdings America Corporation 
 200 Summit Lake Drive 

Valhalla, New York 10595-1356 
 F: +1-914-789-8514 

Section 23. 
 Choice of Law 

This Agreement shall be construed and enforced in accordance with the laws of the [***] except that its choice of law rules shall not be invoked for the
purpose of applying the law of another jurisdiction. 
 Section 24. 

Waiver/Severability 
 No waiver of any provision of
this Agreement, whether by conduct or otherwise, in any one or more instances shall be deemed to be or be construed as a further or continuing waiver of any such provision, or of any other provision or condition of this Agreement. If any provisions
hereof shall be determined to be invalid or unenforceable, the validity and effect of the other provisions of this Agreement shall not be affected thereby. 

Section 25. 
 Nonsolicitation 

For the term of this Agreement [***] neither Alder nor Fujifilm shall, directly, solicit, or attempt to solicit on behalf of Alder or Fujifilm, as the case may
be, any employees of the other who were directly involved in the Programs, unless otherwise approved by the other Party. The foregoing shall not preclude a Party from soliciting or hiring a person responding to a job posting, notice or general
advertising for a position. 
 Section 26. 
 Entire
Agreement; Modification/Counterparts 
  

	 	a)	This instrument including the attached Appendices sets forth the entire agreement between the Parties hereto with respect to the performance of the Programs by Fujifilm for Alder and as such, supersedes all prior and
contemporaneous negotiations, agreements, representations, understandings, and commitments with respect thereto and shall take precedence over all terms, conditions and provisions on any purchase order form or form of order acknowledgment or other
document purporting to address the same subject matter. This Agreement shall not be changed or modified in any manner except by an instrument signed by the duly authorized officers of each of the Parties hereto, which instrument shall make specific
reference to this Agreement and shall express the plan or intention to modify same. For the avoidance of doubt, this Agreement neither affects, replaces nor supersedes the Prior BSA or the Prior QA, the terms of which shall remain in fun force and
effect as set forth therein in relation to activities, rights, liabilities and obligations of each party thereunder. 

  

	 	b)	This Agreement may be executed in one or more counterparts each of which shall be deemed an original but all of which together shall constitute one and the same instrument. 

 

	 	c)	This Agreement becomes effective and binding on all Parties on and as of the last date that the Parties hereto have executed this Agreement. 

[signatures on following page] 

  
 25 

 [***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
  

									
	Alder BioPharmaceuticals, Inc.	 		 	FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
					
	By:	 	 /s/ Mark J. Litton
	 		 	By:	 	 /s/ Henrik Edeback

					
	Name:	 	 Mark J. Litton
	 		 	Name:	 	 Henrik Edeback

					
	Title:	 	 CBO
	 		 	Title:	 	 VP Finance

					
	Date:	 	 10/16/13
	 		 	Date:	 	 Oct 16, 2013

				
		 		 		 	FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
					
		 		 		 	By:	 	 /s/ Stephen A. Spearman

					
		 		 		 	Name:	 	 Stephen A. Spearman

					
		 		 		 	Title:	 	 President

					
		 		 		 	Date:	 	 16 October 2013

				
		 		 		 	FUJIFILM Diosynth Biotechnologies UK Limited
					
		 		 		 	By:	 	 /s/ Stephen C. Tayler

					
		 		 		 	Name:	 	 Stephen C. Tayler

					
		 		 		 	Title:	 	 VP Commercial

					
		 		 		 	Date:	 	 16 October 2013

  
 26

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}]]